Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates

药代动力学 药物开发 治疗窗口 药效学 药理学 医学 药品 治疗指标 抗体-药物偶联物 抗体 免疫学 单克隆抗体
作者
Eshita Khera,Greg M. Thurber
出处
期刊:BioDrugs [Springer Nature]
卷期号:32 (5): 465-480 被引量:43
标识
DOI:10.1007/s40259-018-0302-5
摘要

Antibody-drug conjugate (ADC) development has evolved greatly over the last 3 decades, including the Food and Drug Administration (FDA) approval of several new drugs. However, translating ADCs from the design stage and preclinical promise to clinical success has been a major hurdle for the field, particularly for solid tumors. The challenge in clinical development can be attributed to the difficulty in connecting the design of these multifaceted agents with the impact on clinical efficacy, especially with the accelerated development of 'next-generation' ADCs containing a variety of innovative biophysical developments. Given their complex nature, there is an urgent need to integrate holistic ADC characterization approaches. This includes comprehensive in vivo assessment of systemic, intratumoral and cellular pharmacokinetics, pharmacodynamics, toxicodynamics, and interactions with the immune system, with the aim of optimizing the ADC therapeutic window. Pharmacokinetic/pharmacodynamic factors influencing the ADC therapeutic window include (1) selecting optimal target and ADC components for prolonged and stable plasma circulation to increase tumoral uptake with minimal non-specific systemic toxicity, (2) balancing homogeneous intratumoral distribution with efficient cellular uptake, and (3) translating improved ADC potency to better clinical efficacy. Balancing beneficial immunological effects such as Fc-mediated and payload-mediated immune cell activation against harmful immunogenic/toxic effects is also an emerging concern for ADCs. Here, we review practical considerations for tracking ADC efficacy and toxicity, as aided by high-resolution biomolecular and immunological tools, quantitative pharmacology, and mathematical models, all of which can elucidate the relative contributions of the multitude of interactions governing the ADC therapeutic window.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
liu完成签到,获得积分10
2秒前
4秒前
阿巴阿巴发布了新的文献求助10
6秒前
8秒前
xh完成签到,获得积分20
9秒前
9秒前
Giny发布了新的文献求助10
9秒前
ZZ完成签到 ,获得积分10
11秒前
dada发布了新的文献求助10
13秒前
13秒前
mxq发布了新的文献求助10
14秒前
liourg发布了新的文献求助10
15秒前
Ava应助爱撒娇的书翠采纳,获得10
19秒前
CKJ发布了新的文献求助10
22秒前
sissiarno应助炙热柚子采纳,获得200
24秒前
25秒前
陈吉止完成签到,获得积分10
26秒前
ugk发布了新的文献求助10
29秒前
29秒前
30秒前
无花果应助陈吉止采纳,获得10
30秒前
卞仁吉发布了新的文献求助10
35秒前
爆米花应助科研通管家采纳,获得10
36秒前
ceeray23应助科研通管家采纳,获得10
36秒前
上官若男应助科研通管家采纳,获得10
36秒前
酷波er应助科研通管家采纳,获得10
36秒前
乐乐应助科研通管家采纳,获得10
36秒前
8R60d8应助科研通管家采纳,获得10
36秒前
FIN应助科研通管家采纳,获得10
36秒前
8R60d8应助科研通管家采纳,获得10
36秒前
酷波er应助科研通管家采纳,获得10
36秒前
ceeray23应助科研通管家采纳,获得10
36秒前
FIN应助科研通管家采纳,获得10
36秒前
FIN应助科研通管家采纳,获得10
36秒前
pluto应助科研通管家采纳,获得30
37秒前
8R60d8应助科研通管家采纳,获得10
37秒前
37秒前
37秒前
ceeray23应助科研通管家采纳,获得30
37秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 2000
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1040
Les Mantodea de Guyane Insecta, Polyneoptera 1000
지식생태학: 생태학, 죽은 지식을 깨우다 600
Crystal structures of UP2, UAs2, UAsS, and UAsSe in the pressure range up to 60 GPa 570
Mantodea of the World: Species Catalog Andrew M 500
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3465478
求助须知:如何正确求助?哪些是违规求助? 3058648
关于积分的说明 9062429
捐赠科研通 2748998
什么是DOI,文献DOI怎么找? 1508231
科研通“疑难数据库(出版商)”最低求助积分说明 696880
邀请新用户注册赠送积分活动 696535